Evidence map›Paper›PMID 31001696›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020

The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.

Erofili Papadopoulou, Ourania Nicolatou-Galitis, Ioannis Papassotiriou, Helena Linardou, Aikaterini Karagianni, Konstantinos Tsixlakis, Anthi Tarampikou, Kelly Michalakakou, Emmanouil Vardas, Dimitrios Bafaloukos

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Erofili PapadopoulouClinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, 2 Thivon street, Goudi, Athens, Greece. erofilpa@hotmail.com.
Ourania Nicolatou-GalitisClinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, 2 Thivon street, Goudi, Athens, Greece.
Ioannis PapassotiriouDepartment of Clinical Biochemistry, 'Aghia Sophia' Children's Hospital, Thivon and Papadiamantopoulou street, Goudi, Athens, Greece.
Helena LinardouOncology Unit, 'Metropolitan Hospital', 9 Ethnarxou Makariou Avenue, Athens, Greece.
Aikaterini KaragianniClinic of Oral Diagnosis and Radiology, Dental School, National and Kapodistrian University of Athens, 2 Thivon street, Goudi, Athens, Greece.
Konstantinos TsixlakisClinic of Oral Diagnosis and Radiology, Dental School, National and Kapodistrian University of Athens, 2 Thivon street, Goudi, Athens, Greece.
Anthi Tarampikou1st Oncology Department, 'Metropolitan Hospital', 9 Ethnarxou Makariou Avenue, Piraeus, Greece.
Kelly MichalakakouDepartment of Clinical Biochemistry, 'Aghia Sophia' Children's Hospital, Thivon and Papadiamantopoulou street, Goudi, Athens, Greece.
Emmanouil VardasClinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, 2 Thivon street, Goudi, Athens, Greece.
Dimitrios Bafaloukos1st Oncology Department, 'Metropolitan Hospital', 9 Ethnarxou Makariou Avenue, Piraeus, Greece.
National and Kapodistrian University of Athens · GRMetropolitan Hospital · GRChildren's Hospital Agia Sophia · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCrevicular fluid was used to assess interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) in cancer patients receiving zoledronic acid and/or bevacizumab. The markers were also assessed in the serum.

methodsTwenty-five patients were included and comprised three groups: patients who received zoledronic acid (n = 9), patients who received bevacizumab (n = 9), and patients who received zoledronic acid combined with bevacizumab (n = 5). One patient received zoledronic acid and everolimus and another received zoledronic acid, bevacizumab, and temsirolimus. IL-17 and VEGF were measured by standard quantitative ELISA kits and assessed in two study points.

resultsTwenty-four patients maintained good periodontal health; one had asymptomatic osteonecrosis of the jaw. First assessment: 44 samples were collected; 21 from serum and 23 from crevicular fluid. Second assessment, 6 months later: 11 samples were collected; 6 from serum and 5 from crevicular fluid. IL-17 was detected in all samples, in serum and crevicular fluid, and remained unchanged at both time points. Serum VEGF in patients with bevacizumab alone or combined with zoledronic acid was significantly lower compared with that of patients who received zoledronic acid alone. VEGF was not detected in the crevicular fluid.

conclusionsCrevicular fluid might be an easy, non-invasive means to assess IL-17. The stable values of IL-17 in crevicular fluid and serum and the lack of VEGF in the crevicular fluid could be related to the good periodontal health of our patients. Further studies are needed to assess IL-17 and VEGF in the crevicular fluid in patients with and without periodontal disease.

Indexed as

AgedAged, 80 and overBevacizumabBiomarkersDrug Therapy, CombinationFemaleGingival Crevicular FluidHumansInflammationInterleukin-17MaleMiddle AgedNeoplasmsNeovascularization, PathologicOsteonecrosisPeriodontal DiseasesBevacizumabBiomarkersIL17A protein, humanInterleukin-17Vascular Endothelial Growth Factor AVEGFA protein, humanZoledronic AcidBevacizumabCrevicular fluidInterleukin-17mTOR inhibitorsVEGFZoledronic acid

Identifiers

PMID31001696
OpenAlexW2938617664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.